PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART I. GENERAL NOTIONS OF PAPILLOMAVIRUSES. HUMAN PAPILLOMAVIRUSES-ASSOCIATED CANCERS
https://doi.org/10.17650/1726-9784-2019-19-1-6-12
Abstract
Development of three vaccines intended to prevent cervical cancer (CC) caused by oncogenic human papillomaviruses (HPV) appears to be principal result of research into papillomaviral carcinogenesis. Two of these vaccines efficient in prophylaxis of about 70 % of new CC cases have been recommended for application in Russia. Up till now preventive HPV-vaccinations are not included into the Russian National Vaccination Shedule. In addition to CC HPV are known as etiological agents of some other anogenital as well as certain head and neck tumors. The overall cancer statistics data are found to vary owing to socioeconomic inequalities extremely dramatically for the most preventable cancers. The review is dedicated to major achievements and certain challenges in the field of oncogenic HPV studies.
About the Author
G. M. Volgareva
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Human Papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1–636.
2. Biological agents. IARC Monogr Eval Carcinog Risks Hum 2011; 100(Pt. B):1–441.
3. McBride A.A., Münger K. Expert views on HPV infection. Viruses 2018;10(2):94. DOI: 10.3390/v10020094.
4. Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92(9):690–8. DOI: 10.1093/jnci/92.9.690.
5. Zur Hausen H. Papillomaviruses – to vaccination and beyond. Biochemistry (Mosc.) 2008;73(5):498–503. DOI: 10.1134/S0006297908050027.
6. Zur Hausen H. HPV vaccines: what remains to be done? Interview by Lauren Constable. Expert Rev Vaccines 2011;10(11):1505–7. DOI: 10.1586/erv.11.128.
7. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. DOI: 10.3322/caac.21551.
8. Forman D., de Martel C., Lacey C.J. et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl. 5:12–23. DOI: 10.1016/j.vaccine.2012.07.055.
9. Rigoni-Stern D. Fatti Statistici relativi alle malattie cancerose che Servirono di Base Alle Poche Cose Dette dal Dott. G Servire Progr Path Tera 1842;2:507–17.
10. Zur Hausen H. Papillomaviruses in the causation of human cancer – a brief historical account. Virology 2009;384(2):260–5. DOI: 10.1016/j.virol.2008.11.046.
11. Zur Hausen H., Meinhof W., Scheiber W., Bornkamm G.W. Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridization with complementary RNA of human wart virus. Int J Cancer 1974;13(5):650–6. DOI: 10.1002/ijc.2910130509.
12. Gissmann L., zur Hausen H. Human papilloma virus DNA: physical mapping and genetic heterogeneity. Proc Natl Acad Sci U S A 1976;73(4):1310–3. DOI: 10.1073/pnas.73.4.1310.
13. De Villiers E.-M., Fauquet C., Broker T.R. et al. Classification of papillomaviruses. Virology 2004;324(1):17–27. DOI: 10.1016/j.virol.2004.03.033.
14. Bernard H.U., Burk R.D., Chen Z. et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401(1):70–9. DOI: 10.1016/j.virol.2010.02.002.
15. Van Doorslaer K., Bernard H.U., Chen Z. et al. Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol 2011;19(2):49–50. DOI: 10.1016/j.tim.2010.11.004.
16. Korolenkova L.I., Ermilova V.D. The role of transformation zone as an object of HPV oncogenic impact in CIn and invasive cervical cancer development: clinical considerations. Arkhiv patologii = Arch Pathol 2011;73(6):33–7. (In Russ.).
17. Dyson N., Howley P.M., Münger K. et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243(4893):934–7. DOI: 10.1126/science.2537532.
18. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248(4951):76–9. DOI: 10.1126/science.2157286.
19. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380(6569):79–82. DOI: 10.1038/380079a0.
20. Duensing S., Lee L.Y., Duensing A. et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 2000;97(18):10002–7. DOI: 10.1073/pnas.170093297.
21. Human Papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995;64:1–378. 22. Xiong W.-M., Xu Q.-P., Li X. et al. The association between human papillomavirus infection and lung cancer: a system review and meta-analysis. Oncotarget 2017;8(56):96419–32. DOI: 10.18632/oncotarget.21682.
22. Lawson J.S., Glenn W.K., Salyakina D. et al. Human papilloma virus identification in breast cancer patients with previous cervical neoplasia. Front Oncol 2015;5:298. DOI: 10.3389/fonc.2015.00298.
23. Yang L., Xie S., Feng X. et al. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: a meta-analysis. Sci Rep 2015;5:14667. DOI: 10.1038/srep14667.
24. Volgareva G.M., Ermilova V.D. Detection of human papillomavirus type 18 oncogene E7 in patients with prostate cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian J Biother 2019;18(1):37–41.(In Russ.).
25. Zhang S.-K., Guo L.-W., Chen Q. et al. The association between human papillomavirus 16 and esophageal cancer in Chinese population: a meta-analysis. BMC Cancer 2015;15:99. DOI: 10.1186/s12885-015-1096-1.
26. Al-Shabanah O.A., Hafez M.M., Hassan Z.K. et al. Human papillomavirus genotyping and integration in ovarian cancer Saudi patients. Virol J 2013;10:343. DOI: 10.1186/1743-422X-10-343.
27. Li Y.X., Zhang L., Simayi D. et al. Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 level in patients with colorectal cancer. PLoS One 2015;10(2):0118391. DOI: 10.1371/journal.pone.0118391.
28. Li N., Yang L., Zhang Y. et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011;204(2):217–23. DOI: 10.1093/infdis/jir248.
29. Golovina D.A., Ermilova V.D., Zavalishina L.E. et al. Loss of cell differentiation in HPV-associated bladder cancer. Bull Exp Biol Med 2016;161(1):96–8. DOI: 10.1007/s10517-016-3354-x.
30. Knör M., Tziridis K., Agaimy A. et al. Human papillomavirus (HPV) prevalence in nasal and antrochoanal polyps and association with clinical data. PLoS One 2015;10(10):0141722. DOI: 10.1371/journal.pone.0141722.
31. Eftekhaar N.S., Karbalaie Niya M.H., Izadi F. et al. Human papillomavirus (HPV) genotype distribution in patients with recurrent respiratory papillomatosis (RRP) in Iran. Asian Pac J Cancer Prev 2017;18(7):1973–6. DOI: 10.22034/APJCP.2017.18.7.1973.
32. Katsenos S., Becker H.D. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transtormation: apropos of two cases and a brief literature review. Case Rep Oncol 2011;4(1):162–71. DOI: 10.1159/000327094.
33. Karpishchenko S., Katinas E., Kucherova L. Recurrent respiratory papillomatosis. Vrach = The doctor 2012;1:11–4. (In Russ.).
34. Mitsumoto G.L., Bernardi F.D.C., Paes J.F. et al. Juvenile-onset recurrent respiratory papillomatosis with pulmonary involvement and carcinomatous transformation. Autops Case Rep 2018;8(3):2018035. DOI: 10.4322/acr.2018.035.
35. Wu X., Wang G., Chen X. et al. Impaired T Cell-dependent humoral immune response associated with juvenile-onset recurrent respiratory papillomatosis progression. Sci Rep 2016;6:36378. DOI: 10.1038/srep36378.
36. Holm A., Nagaeva O., Nagaev I. et al. Lymphocyte profile and cytokine mRNA expression in peripheral blood mononuclear cells of patients with recurrent respiratory papillomatosis suggest dysregulated cytokine mRNA response and impaired cytotoxic capacity. Immun Inflamm Dis 2017;5(4):541–50. DOI: 10.1002/iid3.188.
37. Tjon Pian Gi R.E., San Giorgi M.R.M., Pawlita M. et al. Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2016;273(10):3231–6. DOI: 10.1007/s00405-016-4085-3.
38. Mauz P.S., Schafer F.A., Iftner T., Gonser P. HPV vaccination as preventive approach for recurrent respiratory papillomatosis – a 22-year retrospective clinical analysis. BMC Infect Dis 2018;18:343. DOI: 10.1186/s12879-018-3260-0.
39. Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39. DOI: 10.1186/1471-2334-13-39.
40. De Martel C., Plummer M., Vignat J., Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017;141(4):664–70. DOI: 10.1002/ijc.30716.
41. Morrison C., Catania F., Wakely P. Jr., Nuovo G.J. Highly differentiated keratinizing squamous cell cancer of the cervix: a rare, locally aggressive tumor not associated with human papillomavirus or squamous intraepithelial lesions. Am J Surg Pathol 2001;25(10):1310–5. DOI: 10.1097/00000478-200110000- 00013.
Review
For citations:
Volgareva G.M. PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART I. GENERAL NOTIONS OF PAPILLOMAVIRUSES. HUMAN PAPILLOMAVIRUSES-ASSOCIATED CANCERS. Russian Journal of Biotherapy. 2020;19(1):6-12. (In Russ.) https://doi.org/10.17650/1726-9784-2019-19-1-6-12
Views:
607
Email this article 
